Dasatinib-Induced Pulmonary Arterial Hypertension.

INTRODUCTION: Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined. CASE SUMMARY: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months. CONCLUSIONS: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.